Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Abroad (travel likely)RecruitingPHASE2

Conditions

Bladder Cancer · Non-Muscle Invasive Bladder Cancer (NMIBC) · Urothelial Carcinoma · Carcinoma in Situ (CIS) · High-Grade Papillary Bladder Tumors · BCG-Unresponsive Bladder Cancer · Ta Stage Bladder Cancer · T1 Stage Bladder Cancer · BCG-Refractory Bladder Cancer · High-Risk NMIBC · Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Iowa, Iowa City, Iowa, United States
Contact: Study coordinator (Denise Juhr, BS) · denise-juhr@uiowa.edu · (319) 467-6313
Contact: Study coordinator (Mohamad A Abou Chakra, MD) · mohamad-abouchakra@uiowa.edu
Contact: Principal Investigator (Michael A O'Donnell, MD)

Study leads

Michael A O'Donnell, MD
Principal Investigator
University of Iowa

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Gainesville, United States

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE1

North Melbourne, Australia

Telehealth Intervention for Ostomy Self-Management

Colorectal Cancer · Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

A Beta-only IL-2 ImmunoTherapY Study

Advanced Solid Tumor · Unresectable Solid Tumor · Clear Cell Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Diego, United States · San Francisco, United States